Dsuvia: A Dull US FDA Review Preceded The Controversial Approval
Executive Summary
US FDA's review of AcelRx's opioid Dsuvia did not presage the external fireworks that came following the approval.
You may also be interested in...
Dsuvia Gets Warning Letter As US FDA’s Opioid Decisions Complicate Commissioner Race
AcelRx oversimplified Dsuvia’s ease of use, Office of Prescription Drug Promotion says. Focus on opioid safety comes as critics of Janet Woodcock have pointed to FDA’s decisions in the space as disqualifying her for FDA commissioner. Letter appears to reflect long-standing FDA concerns: Dsuvia was approved with a REMS related to administration issues, and Xeris received a similar warning letter last year for exaggerating the ease of use of its glucagon pre-filled syringe Gvoke PFS.
Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
Variety Of Impacts COVID-19 Poses For Biopharma Reflected In Earnings Calls
Several firms reporting quarterly earnings this week discussed how the outbreak is affecting supply chains, drug launches and clinical trials.